DEERFIELD, Ill.  Baxter International Inc. (NYSE: BAX) has appointmented Carlos Alonso president of Baxter Latin America, effective immediately.

"With experience spanning multiple Baxter businesses and geographies, Carlos has the ability to make an immediate positive impact on our business in Latin America," said John J. Greisch, corporate vice president and president of Baxter's international operations. "Through his strategic leadership ability and general management experience, I am confident we will continue to expand Baxter's presence in this important region."

In his new role, Alonso will oversee all Baxter businesses and operations in Latin America. This region includes facilities in Argentina, Brazil, Central America, Chile, Colombia, Mexico and Venezuela, and had 2005 sales of approximately $1 billion. Alonso fills the position vacated by Marcelo A. Mosci, who will be leaving the company.

Since September 2004, Alonso has been general manager of Baxter operations in Brazil, Argentina and Chile. In more than a decade with Baxter, he has held senior positions in Baxter's BioScience and Renal businesses, working in Latin America, Europe and Canada prior to assuming his current role in Latin America. Before joining Baxter, Alonso was the country manager in Spain for Dentsply, a global dental products company.

Alonso earned a chemical engineering degree from Universidade Federal do Paran in Brazil, a master of science degree in the same area from Instituto Quimico de Sarri in Spain, and a master in management from IESE-Universidad de Navarra in Spain.

About Baxter

Baxter Healthcare Corporation is the principal domestic operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

More Voices